Peptides DB
Research-centric peptide and protocol reference hub
Study 28 of 31Octreotide literatureEndocrine connections · RCT2026

Differential Somatostatin Sensitivity of Corticotropic and Somatotropic Responses Following Amino Acid Infusion.

Somatostatin significantly suppresses growth hormone secretion during amino acid infusion, while ACTH and cortisol responses are partly preserved, indicating differential sensitivity.

Read at Endocrine connectionsAdd to compare

Where it sits

this study against the rest of the octreotide corpus
1
Preclinical
25
Observational
0
Open-label
3
Randomised · this one
2
Reviews

Summary and findings

This study measured the differential effects of amino acid infusion on hormone secretion in 15 healthy adults, specifically focusing on ACTH, cortisol, and growth hormone responses. Participants received amino acid and somatostatin analogue infusions at specified rates. The results indicated that somatostatin significantly suppressed growth hormone secretion while partially preserving ACTH and cortisol responses.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as Endocrine connections supplied them

<h4>Objective</h4>Amino acids stimulate pituitary hormone secretion, but whether somatostatin-sensitive pathways differentially regulate activation of the corticotropic and somatotropic axes during amino acid infusion remains unclear. We investigated whether somatostatin signaling constrains growth hormone secretion following amino acid infusion differently from ACTH and cortisol responses in humans.<h4>Methods</h4>We conducted a randomized, within-subject crossover study in 15 healthy adults with three morning visits: amino acid infusion plus saline, somatostatin analogue infusion plus saline, and combined amino acid plus somatostatin analogue infusion. Vamin, an amino acid mixture, was infused at 331 mg·kg-1·h-1 from 0-45 min, and octreotide, a somatostatin analogue, at 200 ng·kg-1·min-1 from -75-165 min; blood was sampled from -75 to 300 min. Post hoc exploratory outcomes included baseline-subtracted area-under-the-curve measures for cortisol, ACTH, and growth hormone, analysed using repeated-measures mixed-effects models.<h4>Results</h4>Following amino acid infusion, ACTH and cortisol showed rapid responses peaking around 45 min, whereas growth hormone increased gradually and peaked around 120 min. Compared with somatostatin analogue alone, amino acid infusion increased peak concentrations and baseline-subtracted exposures for cortisol, ACTH, and growth hormone. Co-infusion with somatostatin analogue substantially reduced ACTH and cortisol responses but almost completely abolished growth hormone secretion.Conclusion: Corticotropic and somatotropic responses were observed following intravenous amino acid infusion in humans, with markedly different somatostatin sensitivity. Growth hormone secretion was almost completely suppressed by somatostatin analogue administration, whereas ACTH and cortisol responses remained partly preserved, suggesting that HPA-axis activation can partly escape somatostatin inhibition.

Elsewhere in the Octreotide corpus

CActivation of the dopamine D2 receptor enhances colonic motility via disinhibition of somatostatinergic signalling in rodents.European journal of pharmacology · 2026 · Not reported in abstract.AnimalBMetastatic proinsulin-secreting tumor: a rare cause of persistent hypoglycemia.JCEM case reports · 2023 · n=1 · Not reported in abstract.HumanCThe Extent of Ligand-Receptor Interactions for Actively Targeted Nanoparticles as a Function of Ligand Density and Receptor Expression.ACS applied materials & interfaces · 2026 · Not reported in abstract.In vitroBLesion-level Quantitative Post-therapy SPECT/CT During &lt;sup&gt;177&lt;/sup&gt;Lu-DOTATATE PRRT for NET Liver Metastases.Anticancer research · 2023 · n=12 · Lesion volume, kBq/ml max, and SUVmax significantly decreased from baseline to final evaluation (all p<0.01).HumanBDOTATATE-PET in custom spheno-orbital implant design for meningiomas with orbital involvement: a case series.Neurosurgical focus · 2026 · n=4 · Not reported in abstract.HumanBOctreotide Administration Methods in Sulfonylurea Poisoning: A Retrospective Chart Review.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2026 · n=29 · Median post-octreotide hypoglycemic events were zero for bolus, 1.5 for infusion, and zero for subcutaneous groups.Human